Royalty Pharma (RPRX) and PureTech Health (PRTC) announced that Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ (KRTX) KarXT for up to $500M with $100M in cash up front and up to $400M in additional payments contingent on the achievement of certain regulatory and commercial milestones. As part of this transaction, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on sales up to $2 billion annually, after which threshold Royalty Pharma will receive 33% and PureTech will retain 67% of the royalty payments. PureTech retains its 3.1% equity ownership in Karuna1. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RPRX:
- Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
- PureTech Health sells interest in KarXT to Royalty Pharma for up to $500M
- Royalty Pharma Raises Full Year 2023 Guidance
- Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B
- Royalty Pharma appoints Ashwin Pai as EVP, investments